ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class

A few days after blasting three next-generation JAK inhibitors to treat rheumatoid arthritis for offering “marginal” clinical benefits over AbbVie’s Humira, drug-cost watchdog Institute for Clinical and Economic Review (ICER) took the unusual step of pulling the report, citing the need to change its methodology. Now, the new draft report on RA drugs is out, and ICER has reversed its negative stance on one of those products: AbbVie’s Rinvoq, the company’s all-important Humira follow-up.